Donald Kalkofen was named Chief Financial Officer of Genvor Inc, effective May 18, 2026. As of November 6, 2026, Genvor Inc has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on May 21, 2026, naming 1 appointment (Form 8-K, May 21, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Genvor Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Genvor Inc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-05-21. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Genvor Inc files it.
Also on the record for Genvor Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| December 5, 2025 | Form D, private offering | — | Form D page | Source |
| June 17, 2025 | Form D, private offering | $425K sold | Form D page | Source |
Selling to them or working with them? See who runs Genvor Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Genvor Inc and the records around it.
Genvor Inc elsewhere on the record
- Form D filing Jun 2025
Watch Genvor Inc
Get an email when Genvor Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Genvor Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Genvor Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Genvor Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-21 | In | Chief Financial Officer | 2026-05-18 | 8-K, 2026-05-21 |
Who leads Genvor Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Donald Kalkofen, appointed, effective 2026-05-18 (filed 2026-05-21).
New leaders reset buying decisions — get the Full Report on Genvor Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Genvor Inc, with the record behind each one.
Find candidates like Chief Financial Officer at Genvor IncEvery change, in the filing's words
Appointed: Donald Kalkofen, Chief Financial Officer, effective 2026-05-18
Appointment of Mr. Kalkofen as Chief Financial Officer On May 18, 2026, the board of directors (the "Board") of Genvor Incorporated (the "Company") appointed Donald Kalkofen as the Company's Chief Financial Officer effective as of May 18, 2026.
- Donald Kalkofen, age 63, brings more than 20 years of Chief Financial Officer experience leading finance and operations across biotechnology, financial services, and technology, with a proven track record of guiding companies through initial public offerings and complex capital markets transactions.
- He has deep expertise in capital raises, SEC reporting, SOX implementation, GAAP compliance, audit committee oversight, and investor relations.
- Since October 2024, Mr. Kalkofen has served as a financial consultant for Wave Financial Consulting, LLC, where he is the sole owner/operator of this financial consulting practice.
- From April 2022 to October 2024, Mr. Kalkofen served as Chief Financial Officer of Alpha Cognition, Inc. (Nasdaq: ACOG; formerly, CSE: ACOG), a CNS-focused biotechnology company, where he oversaw and managed the preparations for the company's initial public offering.
- From 2019 to 2022, Mr. Kalkofen served as Chief Financial Officer of Protagonist Therapeutics Inc. (Nasdaq: PTGX), a biopharmaceutical company.
- Earlier in his career, Mr. Kalkofen held Chief Financial Officer and senior finance leadership roles at Symantec Corporation and West Coast Bancorp, having begun his career as an auditor with PricewaterhouseCoopers.
- Mr. Kalkofen has a B.A. in accounting from Washington State University and is a Certified Public Accountant (inactive).
Tools for this story
Each opens in a new tab, filled in for Genvor Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.